$ZENA ZenaTech, Inc. announces its financial results for

New Post Public Reply Private Reply Replies (0) Message Board
trooperstocks
92
$ZENA ZenaTech, Inc. announces its financial results for the three months ended March 31, 2026. Highlights included revenue of $8.4 million, representing a 640% increase from the same period in 2025. All financial figures are reported in Canadian dollars.

“The first quarter of 2026 was another record-breaking quarter for ZenaTech as we executed on our strategy of acquiring legacy land survey companies and experienced licenced operators with longstanding customers and migrating them to Drone as a Service drone-based automation,” said

@ShaunPassleyPhD

, ZenaTech Chairman, President, and Chief Executive Officer. “Total revenue for the first quarter was $8.4 million, representing approximately 640% growth over the first quarter of 2025. Currently, with 26 DaaS locations now operating across ten US states, Canada, UK, Ireland, UAE, and Australia, and the continued progression of our defense technology pipeline, we believe the fundamental trajectory of the business remains strong and will continue to grow as the demand for our integrated suite of cost-effective drone services and solutions accelerates in 2026.”

Read the full report here: https://zenatech.com/zenatech-reports-640-inc...-division/

$ZENA

$49Q #ZenaTech #DroneasaService #DaaS #AIDrones #DefenseTech #CounterUAS #EnterpriseSaaS #QuantumComputing #BlueUAS #AutonomousSystems #DroneTechnology #RevenueGrowth #Innovation #FutureOfFlight

https://x.com/ZenatechInc/status/2062201684970082797

ZenaTech Inc. (ZENA) Stock Research Links

ZENA Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Huawei Introduces Innovative Wearables for Enhanced Connectivity

Updated Category News Views 293

Huawei Unveils Next-Generation Wearables and Tablets At a much-anticipated event, Huawei Consumer Business Group (CBG) revealed a thrilling array of new products. This launch showcased a strong emphasis on trendy wearables and sophisticated tablets, highlighting the brand's dedication to innovation and a user-friendly design. Chic Wearables for Style and Utility Among the...

Continue Reading
Investigating Barnes & Noble Education: Shareholder Rights Explained

Updated Category News Views 155

Understanding the Investigation of Barnes & Noble Education In a proactive move for investors, the law firm Bragar Eagel & Squire, P.C. is currently investigating Barnes & Noble Education, Inc. (BNED). This investigation aims to determine whether the company potentially breached federal securities laws or engaged in unlawful business practices that could lead to...

Continue Reading
Bailey Kennedy Achieves Landmark Legal Win for Talisman Group

Updated Category News Views 171

Bailey Kennedy Achieves Legal Victory for Talisman Group Judge Rules LNW Violated Talisman's Distribution Agreement by Marketing Competing Game In a significant legal development, Bailey Kennedy, LLP has successfully represented The Talisman Group, LLC, the innovative minds behind EZ Baccarat. The firm has recently triumphed in a legal dispute against LNW Gaming, Inc.,...

Continue Reading
Join the Class Action Lawsuit Against Ardelyx, Inc. Now

Updated Category News Views 49

Join the Class Action Lawsuit Against Ardelyx, Inc. Attention Ardelyx, Inc. investors! There's an important class action lawsuit underway, and this is your opportunity to get involved. Bronstein, Gewirtz & Grossman, LLC, a respected law firm known for its dedication to investor advocacy, has announced a class action case involving Ardelyx, Inc. (NASDAQ: ARDX) and certain...

Continue Reading
Aileron Therapeutics Unveils Q3 2024 Financial Performance

Updated Category News Views 97

Aileron Therapeutics Reports Impressive Q3 2024 Financial Results Aileron Therapeutics, Inc. (NASDAQ: ALRN), a biopharmaceutical company committed to developing innovative medicines for orphan pulmonary diseases, has recently showcased significant progress with their third-quarter financial results. This quarter has been marked by promising advancements in clinical trials...

Continue Reading